Jacobsen Capital Management Increases Stock Position in Johnson & Johnson $JNJ

Jacobsen Capital Management raised its holdings in Johnson & Johnson (NYSE:JNJ) by 54.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,892 shares of the company’s stock after purchasing an additional 1,722 shares during the period. Jacobsen Capital Management’s holdings in Johnson & Johnson were worth $747,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Argus set a $210.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $192.81 on Thursday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The firm has a fifty day moving average of $181.64 and a 200-day moving average of $165.56. The firm has a market capitalization of $464.35 billion, a P/E ratio of 18.61, a PEG ratio of 2.25 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion during the quarter. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.